|
521 |
Ridaforolimus
Enthalten in Drugs in R & D Bd. 10, 27.11.2012, Nr. 3, date:9.2010: 165-178
|
|
|
|
522 |
Risk Assessment in Extrapolation of Pharmacokinetics from Preclinical Data to Humans
Enthalten in Clinical pharmacokinetics Bd. 49, 18.12.2012, Nr. 9, date:9.2010: 619-632
|
|
|
|
523 |
Risk Evaluation and Mitigation Strategies (REMS)
Enthalten in Drug safety Bd. 35, 20.11.2012, Nr. 2, date:2.2012: 91-104
|
|
|
|
524 |
Risk Minimization Activities of Centrally Authorized Products in the EU
Enthalten in Drug safety Bd. 35, 9.1.2013, Nr. 4, date:4.2012: 299-314
|
|
|
|
525 |
Rivastigmine Transdermal Patch Skin Tolerability
Enthalten in Clinical drug investigation Bd. 30, 28.8.2012, Nr. 1, date:1.2010: 41-49
|
|
|
|
526 |
RNA Interference Technologies and Therapeutics
Enthalten in BioDrugs Bd. 23, 16.8.2012, Nr. 5, date:10.2009: 305-332
|
|
|
|
527 |
Roflumilast
Enthalten in Drugs Bd. 70, 19.9.2012, Nr. 12, date:8.2010: 1615-1627
|
|
|
|
528 |
Role of Cannabinoids in Multiple Sclerosis
Enthalten in CNS drugs Bd. 25, 1.3.2011, Nr. 3, date:3.2011: 187-201
|
|
|
|
529 |
Role of Emerging Antithrombotic Therapy in the Prevention of Cardioembolic Complications in Patients with Atrial Fibrillation
Enthalten in American journal of cardiovascular drugs Bd. 11, 17.8.2012, Nr. 4, date:8.2011: 265-275
|
|
|
|
530 |
Role of Heart Rate in Cardiovascular Diseases
Enthalten in American journal of cardiovascular drugs Bd. 9, 20.8.2012, Nr. 1, date:12.2009: 9-12
|
|
Administration
